To define the regulatory roles and therapeutic potential of cGMP signaling in cancer, including differential effects of cGMP in tumor and host stromal cells.
In the Fukumura lab in Boston, the doctoral researchers will be trained in cancer biology and multiphoton intravital microscopy of various tumors (including melanomas) in mice via window models. cGMP sensor mice and cGKI mutant mice have already been transferred from Tübingen to Boston.
Mariagiovanna obtained her B.Sc. in Biotechnology at the University of Padua, Italy, where she developed a strong interest in cancer research. Her Bachelor’s thesis focused on the validation of a new zebrafish reporter line for STAT3, protein which is involved in uncontrolled tumor proliferation. Then, she continued her studies earned her Master’s degree in Industrial Biotechnology in Padua. She did her Master’s thesis in the Functional Genomics Lab of G. Lanfranchi in the Department of Biology and CRIBI Biotechnology Centre, moving her interest on the study of non-coding RNAs, such as miRNAs, to analyse how their expression, if altered, can determine or influence invasiveness and therefore progression in malignant melanoma. After her M.Sc., Mariagiovanna joined in the laboratory of Robert Feil to do her PhD. Here, her research focusses on the role of cGMP signalling in cancer.
Dhayade S, Kaesler S, Sinnberg T, Dobrowinski H, Peters S, Naumann U, Liu H, Hunger RE, Thunemann M, Biedermann T, Schittek B, Simon HU, Feil S, Feil R. Sildenafil potentiates a cGMP-dependent pathway to promote melanoma growth. Cell Rep. 2016;14:2599-610
Thunemann M, Schörg BF, Feil S, Lin Y, Voelkl J, Golla M, Vachaviolos A, Kohlhofer U, Quintanilla-Martinez L, Olbrich M, Ehrlichmann W, Reischl G, Griessinger CM, Langer HF, Gawaz M, Lang F, Schäfers M, Kneilling M, Pichler BJ, Feil R. Cre/lox-assisted noninvasive in vivo tracking and quantification of specific cell populations by positron emission tomography. Nat Commun. 2017;8:444